Not just an anti-eosinophil drug: tezepelumab treatment for type 2 asthma and beyond

Affiliations

• ¹ David Geffen School of Medicine, UCLA, Los Angeles, CA, USA jcorren@ucla.edu.
• ² Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.
• ³ Québec Heart and Lung Institute, Laval University, Quebec City, QC, Canada.
• ⁴ Department of Respiratory Medicine, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.
• ⁵ National Jewish Health, Denver, CO, USA.
• ⁶ Royal Brompton and Harefield Hospitals, School of Immunology and Microbial Sciences, King's College, London, UK.
• ⁷ Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, USA.
• ⁸ Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
• ⁹ Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, USA.
• ¹⁰ Global Medical Affairs, Amgen, Thousand Oaks, CA, USA.